CSRC Presentation.Napa.2015

← Back to document page

6/1/15 1 1 June 2, 2015 NASDAQ: DSCO surfactant : Where We Have and Where We Are Going 2 DISCLOSURE : Christina Joseph, BS, RRT-NPS Clinical R&D Specialist Discovery Labs Discovery Labs is a manufacturer of KL4 and holds patents for Aerosurf technology r 3 Opinions expressed in these slides represent the speaker s own opinions, and not those of speaker s employer or any other organization 6/1/15 2 4 Pulmonary Surfactants and Respiratory Distress Syndrome (RDS) 5 1. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur. Respir. J. 1999;13(6):1455 1476. 2. American Lung Association. State of Lung Disease in Diverse Communities (2010). Available at Accessed August 29, 2012 Neonatal Respiratory Distress Syndrome (RDS) Epidemiology Life-threatening in premature infants, whose lungs have not fully developed surfactant prevents alveolar collapse at low lung volume, and preserves bronchiolar patency during normal and forced respiration1 Most cases occur in babies born before 28 weeks Rare in infants born at full-term 16,268 infants suffered from RDS in 20052 An incidence rate of per 1000 In 2007, 735 deaths, or 17 per 100,000

Less Invasive Surfactant Administration: LISA • This method involves brief tracheal catheterization and has been extensively studied, with surfactant administered by using both a flexible feeding tube and a semi-rigid vascular catheter during nCPAP

  Administration, 2015, Presentation, Invasive, Less, Less invasive surfactant administration, Surfactant, Apna